DXCM Inks Deal With Nanowear to Boost CGM Application Beyond Diabetes
DexCom's recent licensing deal with Nanowear is likely to reinforce the broader potential of CGMs in continuous metabolic ...
Zacks.com on MSN6d
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 Approval
DexCom receives a warning letter from the FDA citing several issues with its popular G6 & G7 sensor manufacturing. The ...
Government of Saskatchewan Expands Public Coverage for Dexcom Continuous Glucose Monitoring Systems
Eligible residents living with diabetes in Saskatchewan who rely on any type of insulin may be eligible to receive coverage ...
pharmaphorum4d
Real-time Abbott glucose monitor available to NHS after UK launch
Meanwhile, the UK launch of Freestyle Libre 3 comes as rival real-time CGM player Dexcom received a European CE mark for its G7 device for people with diabetes aged two years and older.
pharmaphorum1d
Abbott’s OTC glucose monitor ‘will grow the market’
Both companies also sell reimbursable prescription CGMs for type 1 and type 2 diabetes, respectively, the G7 and Libre 3 range ... annual growth rates (CAGR) of CGM devices for insulin-dependent ...
MedTech Dive5d
Newly public Beta Bionics reports sales surge; Dexcom hires CCO
Sales of Beta Bionics insulin pumps spiked 145% in the fourth quarter behind solid new patient starts. Elsewhere, former ...